key: cord-0875566-6fb8qgxo
authors: Liu, Jialin; Liu, Siru
title: The management of coronavirus disease 2019 (COVID‐19)
date: 2020-05-22
journal: J Med Virol
DOI: 10.1002/jmv.25965
sha: d438c507ded56661ce131df5deb0017fe41d4180
doc_id: 875566
cord_uid: 6fb8qgxo

In December 2019, a novel coronavirus causing severe acute respiratory disease occurred in Wuhan, China. It is an emerging infectious disease with widespread and rapid infectiousness. The World Health Organization declared the coronavirus outbreak to be a public health emergency of international concern on 31 January 2020. Severe COVID‐19 patients should be managed and treated in a critical care unit. Performing a chest X‐ray/CT can judge the severity of the disease. The management of COVID‐19 patients includes epidemiological risk and patient isolation; treatment entails general supportive care, respiratory support, symptomatic treatment, nutritional support, psychological intervention, etc. The prognosis of the patients depends upon the severity of the disease, the patient's age, the underlying diseases of the patients, and the patient's overall medical condition. The management of COVID‐19 should focus on early diagnosis, immediate isolation, general and optimized supportive care, and infection prevention and control.

A novel coronavirus causing severe acute respiratory disease emerged recently in Wuhan, China. The World Health Organization (WHO) has declared the coronavirus outbreak to be a public health emergency of international concern on 31 January 2020. As 140 nm. Current research shows it has more than 85% homology with SARSr-CoV (bat-SL-CoVZC45). 3 However, many important questions remain unanswered. For example, there is no certainty about the source of the virus and outbreak, the time span of the patients discharging infective viruses, and the pathogenesis. 3 This article will review the epidemiologic, risk factors, presentation, investigations, management, and discharge of this emerging infectious disease.

The guidelines set forth by the National Health Committee of the People's Republic of China suggest that patients with a severe acute respiratory infection (fever, cough, fatigue) are suspected patients of COVID-19 if they have one of the following epidemiological risk factors. 3 A summary of the epidemiological risk factors is as follows:

(1) A history of travel to or residence in the city of Wuhan, China, or other cities with continuous transmission of local cases in the last 14 days before system onset.

(2) Contact with a confirmed case of COVID-19 in the 14 days before illness onset.

(3) Contact with patients with fever or respiratory symptoms from Wuhan city, China, or other cities with continuous transmission of local cases in the last 14 days before symptom onset.

(4) Clustered onsets.

The incubation period of COVID-19 is 1 to 14 days, usually 3 to 7 days. 3 Huang et al reported mean incubation time is about 5 days (95% confidence interval, 4 to 7 days). 4 The common symptoms of the patients infected with COVID-19 include fever (83%-98.6%), cough (46%-82%), and fatigue (11-69.6%) early on the clinical course. [3] [4] [5] [6] [7] Some patients may have shortness of breath (breathlessness/dyspnea), muscle ache (myalgia), arthralgia, headache, chest pain, chest discomfort, sore throat (pharyngalgia), nasal congestion (rhinobyon), rhinorrhea, throat congestion, tonsil swelling, enlargement of lymph nodes, anorexia, diarrhea, nausea, abdominal pain, vomiting, heart palpitations, hemoptysis, chill, dizziness, expectoration, and so on. [3] [4] [5] [6] [7] [8] [9] [10] The typical initial symptoms of COVID-19 are primarily fever, cough, and fatigue. However, some patients present other symptoms similar to influenza or no obvious symptom of disease onset. 11 Nevertheless, these atypical initial symptoms should be paid the same attention in the diagnosis as the typical symptoms.

The population is generally susceptible to the COVID-19. Though (1) Age more than equal to 65 years.

(2) Pregnant women.

(3) Obesity.

(4) Low immune function (people with HIV infection, people with long-term use of immunosuppressive agents, etc).

(5) Underlying chronic medical conditions (diabetes mellitus, hypertension, cardiovascular diseases, lung disease, cancer, heart failure, cerebrovascular disease, renal disease, liver disease, etc).

After the infection of COVID-19, the elderly and patients with chronic underlying diseases are at the highest risk of the condition becoming more serious. Death cases were more common in the elderly and patients with chronic underlying diseases. 5 Approximately one-third to one-half of severe patients had underlying comorbidities, including diabetes, hypertension, and cardiovascular disease. 5, 6 In another study of patients in intensive care unit (ICU) and non-ICU, patients in ICU were older (median age 66 vs 51) and had more comorbidities (72% vs 37%). 6 Not only are elderly individuals and individuals with underlying chronic medical conditions affected more severely by COVID-19, pregnant women are at a higher risk, as well. During pregnancy, women will have some immune changes, which may lead to the sensitivity and severity of infectious diseases. 15 Compared with the general adult population, pregnant women are more likely to have untoward outcomes. 16 During the current outbreak of COVID-19, pregnant women have a high risk of developing severe infections. 17 

The hematology examination includes complete blood count, electrolytes, blood gas analysis, coagulation test, liver and kidney function, C-reactive protein, erythrocyte sedimentation rate, procalcitonin, lactate dehydrogenase, creatine kinase, myocardial enzyme, myoglobin, lactate, D-dimer, inflammatory factors (interleukin(IL)-6, IL-10, TNF-α), urine routine test, stool routine test, and so on. 3 In these studies, it was found that most patients had normal or decreased white blood cells or lymphopenia in the early phase of the disease. Most patients displayed elevated C-reactive protein level and erythrocyte sedimentation rates, and normal procalcitonin levels. 3, 5, 6 Severe patients were significantly laboratory abnormalities (ie, leukopenia, lymphopenia, thrombocytopenia, elevated C-reactive protein levels) as compared with nonsevere patients (P < .05). 5 

It is imperative to quickly collect and test appropriate specimens of suspected cases under the guidance of laboratory experts. As samples may require multiple tests to confirm the 2019-nCoV, sufficient clinical material is recommended when sampling. The informed consent of the patient or guardian is required during sample collection, testing, and potential future research. The specimens include respiratory specimens (nasopharyngeal and oropharyngeal swabs, bronchoalveolar lavage fluid, inner-tracheal aspirate fluid, nasopharyngeal aspirate fluid, or nasal lavage fluid, sputum, biopsy or autopsy tissue, including lungs, bronchoalveolar fluid Lavage fluid, trachea, and tracheal aspiration fluid) or blood or urine. The specimens were tested by real-time polymerase chain reaction or genetic sequencing for 2019-nCoV. 3,18

Chest images (CT/X-ray imaging) manifestation include: 3, [19] [20] [21] (1) Multiple, patchy, sub-segmental or segmental/lobar ground-glass opacity in unilateral/bilateral.

(2) Multiple, patchy, or large patches of consolidation in unilateral/ bilateral lungs, with a little grid-like or honeycomb-shaped interlobular septal thickening, especially in the middle and lower lobes.

The imaging manifestations of the 2019-nCoV pneumonia are similar to viral pneumonia, but it also has its own imaging characteristics. The image of some patients changes rapidly. 21 Chest X-rays and CT images of severe patients show more significant image abnormalities than non-severe patients. 5 Pulmonary consolidation could be served as a sign of deterioration. 21 6 | MANAGEMENT

The goal of respiratory support is to enable the patient to be adequately oxygenated and ventilated. Respiratory support ensures that the respiratory status of the patient does not deteriorate. 22 If the cause for respiratory distress cannot be quickly identified or corrected, the patient should be provided respiratory support and possibly mechanical ventilation before the complete respiratory collapse. 23 Respiration should be monitored regularly because it is ECMO can be recommended in the following situations 37 :

(1) PaO 2 /FiO 2 < 50 mm Hg > 3 hours;

(2) PaO 2 /FiO 2 < 80 mm Hg > 6 hours;

(3) FiO 2 = 1.0, PaO 2 /FiO 2 < 100 mm Hg;

(4) pH < 7.25, and PaCO 2 > 60 mm Hg > 6 hours, and R > 35 /min; 6.2 | Cope with organs injuries caused by S ARS-CoV-2 SARS-CoV-2 not only may lead to pneumonia, but it may also cause multiple organ and systems injuries. These organs and systems include the liver, the kidneys, cardiovascular system, neurological system, gastrointestinal system injury, immune system, coagulation system, etc. [38] [39] [40] [41] [42] [43] [44] Therefore, we should pay attention to early recognition of multiorgan injuries and optimized supportive care to the protection and prevention thereof in the treatment of COVID-19.

For severe patients and patients with an unsatisfactory therapeutic effect, we should pay attention to organ function and take necessary protective measures, including mechanical ventilation, symptomatic treatment, glucocorticoids, antivirals, antishock therapy, and so on. 45 

Currently, there is no evidence from a randomized controlled trial (RCT) to support specific drug treatment against the COVID-19 in suspected or confirmed cases. 3,46

The α-interferon atomization inhalation, chloroquine or hydroxychloroquine, lopinavir/ritonavir orally, and remdesivir, can be considered.

It is not recommended to use three or more antivirals in combination. 3, 46 Among these drugs, the European Medicines Agency recommended on the compassionate use of remdesivir for COVID-19. 47 National Institutes of Health (NIH) recommended against the use of lopinavir/ ritonavir for the treating of COVID-19, except in the context of a clinical trial. 46 An RCT of 199 patients in China showed that treatment with lopinavir/ritonavir had no benefit beyond standard care. 48 

It is important to avoid blind or inappropriate use of antibacterial, especially combinations of broad-spectrum antibacterial. 3 

The use of corticosteroids for severe ARDS is controversial.

Methylprednisolone can be used as appropriate for patients with rapid disease progression or severe illness. 3,49

Ibuprofen can be used when the temperature is higher than 38.5℃. Renin-angiotensin-aldosterone system inhibitors should be continued in patients in otherwise stable condition who are at risk for, being evaluated for, or who are already diagnosed with COVID-19. 59 However, there is no evidence that patients with COVID-19 should discontinue or continue sodium-dependent glucose transporter 2 (SGLT-2i). 60,61

In the process of treating for COVID-19, the treatments are individualized according to traditional Chinese medicine syndrome diagnosis and treatment (Bian Zheng Lun Zhi). Syndrome differentiation individually is used to guide the selection of traditional Chinese medicine treatment using traditional Chinese medicine herbal formulae. 62 Some drugs and herbal formulae also were recommended for treating COVID-19 in the latest version of China guideline for diagnosis and treatment of COVID-19. 3 However, the therapeutic effect of traditional Chinese medicine warrants further investigation in future studies.

Severe COVID-19 patients should be screened and evaluated for the risk of malnutrition based on the Subjective Global Assessment or the Nutrition Risk Screening 2002 (NRS2002) score. 49, 63 Clinicians must carefully observe patients' response to treatment and adjust nutrition support. In most cases, nutrition support includes food, oral supplements, tube feeding, and parenteral nutrition. It is often used interchangeably on the same patient. 64 For the patients who can oral intake, a diet rich in protein, carbohydrates, and vitamins is recommended. Patients who cannot oral intake but are compatible with enteral nutrition should be given enteral nutrition as soon as possible. For the patients incompatible with enteral nutrition, parenteral nutrition should be given in time to meet the energy needs. 49 

Because COVID-19 is an emerging infectious disease, patients with COVID-19 are often accompanied by anxiety and fear. 3 These patients need appropriate mental health intervention. The mental health interventions include formal psychotherapy for psychiatric disorders and a series of wellness and resilience-based psychosocial interventions for emotional distress and social problems. 65, 66 The common interventions in mental health include psychological first aid, crisis counseling, psychoeducation, family outreach, social support, psychological debriefing (eg, critical event stress debriefing), and techniques for anxiety reduction. [66] [67] [68] [69] [70] [71] During mental health intervention, clinicians should assess and monitor risk and protective factors across all phases of an emergency and disaster. 72 

All patients with COVID-19 need to meet all of the following conditions to be discharged. The body temperature had returned to normal for more than 3 days; the respiratory symptoms had improved significantly; the pulmonary inflammation showed obvious signs of absorption; the nucleic acid test of the respiratory samples was negative for two consecutive times (at least one-day sampling interval); the discharged patients need to be quarantined at home for 14 days. 3 If their condition deteriorates, all discharged patients should be instructed to return to the hospital. 53 COVID-19 is an emerging infectious disease, and continuous efforts are needed to explore effective treatments for this emerging acute respiratory infection. 9 

Guideline for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (Trial Version 6). 2020. Accessed on

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 2019 novel coronavirus infection in China

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province

A familial cluster of pneumonia associated with the 2019 novel person transmission: a study of family cluster

Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care Units-the experience in Sichuan Province, China

A risk classification model to predict mortality among laboratory-confirmed avian influenza A H7N9 patients: a population-based observational cohort study

A comparison of the quick sequential (sepsis-related) organ failure assessment score and the national early warning score in non-ICU patients with/without infection

Emerging infections and pregnancy

Emerging infectious diseases in pregnancy

Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections

WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases

CT imaging features of 2019 novel coronavirus

Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China

Emerging coronavirus 2019-nCoV pneumonia

Adult Critical Care Medicine: A Clinical Casebook

Surgical Critical Care Therapy: a Clinically Oriented Practical Approach

Emergency department hyperoxia is associated with increased mortality in mechanically ventilated patients: a cohort study

Oxygen therapy for acutely ill medical patients: a clinical practice guideline

BTS guideline for oxygen use in adults in healthcare and emergency settings

Respiratory support for severe 2019-nCoV pneumonia suffering from acute respiratory failure: time and strategy

Respiratory & Critical Care Medicine Committee of Chinese Association of Chest Physician. Expert consensus of high-flow nasal cannula oxygen therapy on clinical application regularity

Noninvasive ventilation and survival in acute care settings: a comprehensive systematic review and meta-analysis of randomized controlled trials

Invasive and noninvasive ventilation in the emergency department

An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome

Respiratory & Critical Care Medicine Group of Chinese Thoracic Society. Mechanical ventilation guidelines for patients with acute respiratory distress syndrome (trail)

Prone position for acute respiratory distress syndrome. A systematic review and metaanalysis

Clinical implementation of electric impedance tomography in the treatment of ARDS: a single centre experience

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Recommendations on extracorporeal life support for critically ill patients with novel coronavirus pneumonia

Organ-protective effect of angiotensinconverting enzyme 2 and its effect on the prognosis of COVID-19

Evidence for gastrointestinal infection of SARS-CoV-2

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Liver injury in COVID-19: management and challenges

Neurological manifestations in COVID-19 caused by SARS-CoV-2

Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol

Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia

Comorbidities and multi-organ injuries in the treatment of COVID-19

COVID-19 treatment guideline

European medicines agency. EMA provides recommendations on compassionate use of remdesivir for COVID-19. European medicines agency science medicines health

A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

SARS and MERS: recent insights into emerging coronaviruses

A review of treatment modalities for Middle East Respiratory Syndrome

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected (Interim guidance)

Clinical characteristics of 2019 novel coronavirus infection in China

Government of Canada. Clinical management of patients with moderate to severe COVID-19 -Interim guidance

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention

COVID-19 treatment guideline

Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19

Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?

COVID-19 and diabetes management: what should be considered?

Investigation into the influence of physician for treatment based on syndrome differentiation

The impact of nutritional risk screening 2002 and subjective global assessment upon prognosis for intensive care patients

Educational and Clinical Practice Committee, European Society of parenteral and enteral nutrition. ESPEN Guideline Nutr Screen

Mental health response to community disasters: a systematic review

Disaster psychiatry: principles and practice

American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI)

Psychiatric disorders among transported hurricane evacuees: acute-phase findings in a large receiving shelter site

Systematic review and meta-analysis of multiple-session early interventions following traumatic events

Psychological debriefing for preventing post traumatic stress disorder (PTSD)

Psychosocial interventions in the early phases of disasters

Psychosocial management before, during, and after emergencies and disasters-results from the Kobe Expert Meeting

A novel coronavirus outbreak from Wuhan city in China, rapid need for emergency departments preparedness and response; a letter to editor

The authors declare that there are no conflict of interests.

JL and SL conceived the study. JL and SL performed the collection and analysis of literature and data, and drafted the manuscript. All authors reviewed and approved the final version.

http://orcid.org/0000-0002-1369-4625